Post hoc analysis of the KINGFISHER trial in 91 eyes with diabetic macular oedema: retinal nonperfusion index did not change significantly over 52 weeks with monthly brolucizumab or aflibercept, with no significant difference between agents.
Secondary analysisn = 91
Alhelaly et al. Comparison of Retinal Nonperfusion in Diabetic Macular Edema Treated With Brolucizumab Versus Aflibercept: A KINGFISHER Trial Analysis